Gelovani, TX
Juri Gelovani, Missouri City, TX US
Patent application number | Description | Published |
---|---|---|
20090170131 | Agents for Imaging Apoptosis - Compositions, and methods of using such compositions, having the following Formula (I) or salt, ester, or hydrate thereof, wherein R | 07-02-2009 |
20100196273 | NOVEL AGENT FOR IN VIVO PET IMAGING OF TUMOR PROLIFERATION - Compounds for in vivo diagnostic imaging of cellular proliferation are provided. The compounds include L-nucleosides such as a 2′-deoxy-2′-fluoro-L-ara-binofuranosyl pyrimidine nucleoside analogue. These nucleosides are labeled with a positron emitting radioisotope. The present invention also provides a method for in vivo diagnostic imaging of cellular proliferation. | 08-05-2010 |
20100254896 | METHODS AND COMPOSITIONS RELATED TO ADENOASSOCIATED VIRUS-PHAGE PARTICLES - Embodiments of the invention are generally directed to compositions and methods of delivering one or more transgene to a target cell, such as a tumor cell, in a site-specific manner to achieve enhanced expression and to constructs and compositions useful in such applications. In certain aspects, expression from a therapeutic nucleic acid may be assessed prior to administration of a treatment or diagnostic procedure to or on a subject. | 10-07-2010 |
20100322858 | Radiohaloimatinibs and Methods of Their Synthesis and Use in PET Imaging of Cancers - We disclose methods of synthesizing radiohalidated organic compounds and their use in positron emission tomography (PET) imaging of cancer cells. | 12-23-2010 |
20110097268 | RADIOHALOIMATINIBS AND METHODS OF THEIR SYNTHESIS AND USE IN PET IMAGING OF CANCERS - We disclose methods of synthesizing radiohalidated organic compounds and their use in positron emission tomography (PET) imaging of cancer cells. | 04-28-2011 |
20120178903 | Methods and Compositions Related to Adenoassociated Virus-Phage Particles - Embodiments of the invention are generally directed to compositions and methods of delivering one or more transgene to a target cell, such as a tumor cell, in a site-specific manner to achieve enhanced expression and to constructs and compositions useful in such applications. In certain aspects, expression from a therapeutic nucleic acid may be assessed prior to administration of a treatment or diagnostic procedure to or on a subject. | 07-12-2012 |
Juri Gelovani, Pearland, TX US
Patent application number | Description | Published |
---|---|---|
20090028791 | Dichloroacetate Analogs as Imaging Agents - A compound having structure I: | 01-29-2009 |
20100278730 | Non-Invasive Molecular Imaging of Cellular Histone Deacetylase Substrate Using Magnetic Resonance Spectroscopy (MRS) or Positron Emission Tomography (PET) - We disclose methods of detecting histone deacetylase activity in a mammal by administering to the mammal a compound comprising at least one atom having a nucleus detectable by magnetic resonance spectroscopy, wherein the compound is a substrate of histone deacetylase; and observing the compound or a cleavage product thereof in at least a portion of the body of the mammal by magnetic resonance spectroscopy (MRS). We also disclose methods of detecting histone deacetylase activity in a mammal by administering to the mammal a compound comprising at least one positron-emission-decaying radioisotope, wherein the compound is a substrate of histone deacetylase; and observing the compound or a cleavage product thereof in at least a portion of the body of the mammal by positron emission tomography (PET). We also disclose compounds useful as histone deacetylase substrates. | 11-04-2010 |
Juri G. Gelovani, Houston, TX US
Patent application number | Description | Published |
---|---|---|
20100290997 | Imaging Agents and Methods - The disclosure includes a composition including a poly(L-glutamic acid) and a NIRF dye. It also includes a method including providing to a plurality of cells an imaging agent including poly(L-glutamic acid), a NIRF dye and then imaging the cells to detect the imaging agent. It further includes a dual functional contrast agent including an MRI agent conjugated with an optical imaging agent. A method of detecting cancer is provided including injecting a dual functional contrast agent into a patient and performing both an MRI and an optical scan. The presence of the agent may indicate cancer. A method of detecting cancer by injecting PG-DTPA-Gd-NIR813 into a patient, then detecting the presence or absence of Gd in a cell or tissue of the patient and detecting the presence or absence of NIR813 in a cell or tissue of the patient is provided. The presence of Gd and NIR813 may indicate cancer. | 11-18-2010 |
Juri G. Gelovani, Missouri City, TX US
Patent application number | Description | Published |
---|---|---|
20100062465 | Detection of Histone Deacetylase Inhibition - Provided are compositions and methods for intracellular detection of enzyme activity. One example of a composition is a histone deacetylase substrate comprising a compound of the following formula (I): One example of a method is a method for detecting histone deacetylase activity comprising introducing a compound according to formula (1) to a plurality of cells and monitoring the cells with magnetic resonance spectroscopy. | 03-11-2010 |
20110312007 | Detection of Histone Deacetylase Inhibition - Provided are compositions and methods for intracellular detection of enzyme activity. One example of a composition is a histone deacetylase substrate comprising a compound of the following formula (I): | 12-22-2011 |